Loading…

HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer

Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the HLA-G 3′ untranslated region (UTR) regulate HLA-G expression, we investigated HLA-G 3′UTR...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2019-04, Vol.9 (1), p.5407, Article 5407
Main Authors: Schwich, Esther, Rebmann, Vera, Michita, Rafael Tomoya, Rohn, Hana, Voncken, Jan Willem, Horn, Peter A., Kimmig, Rainer, Kasimir-Bauer, Sabine, Buderath, Paul
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3
cites cdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3
container_end_page
container_issue 1
container_start_page 5407
container_title Scientific reports
container_volume 9
creator Schwich, Esther
Rebmann, Vera
Michita, Rafael Tomoya
Rohn, Hana
Voncken, Jan Willem
Horn, Peter A.
Kimmig, Rainer
Kasimir-Bauer, Sabine
Buderath, Paul
description Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the HLA-G 3′ untranslated region (UTR) regulate HLA-G expression, we investigated HLA-G 3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the HLA-G 3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the HLA-G 3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.
doi_str_mv 10.1038/s41598-019-41900-z
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6443684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2201711228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</originalsourceid><addsrcrecordid>eNp9kc9qFTEUxgdRbKl9ARcScCPYsfk3yWQjlGJvhQtu6jpkMmduU2aSa5Ip2JWv4Wv4SD6JuXdqrS4MgXyH_M45Ofmq6iXB7whm7WnipFFtjYmqOVEY13dPqkOKeVNTRunTR_qgOk7pBpfVUFXY59UBw4rREh9W3y_XZ_UKsZ_ffqDZ52h8Gk2GHkXYuODRrYnO-JzQW0ZauTpdneyUEkUh4_sSYNZcoR4G5wH1zkyQo7NmRHZ0fi9SNnlOe7p3CUwCFOZswwTIeQRbl69hdAUMSzNkjbcQX1TPBjMmOL4_j6rPFx-uzi_r9afVx_OzdW255LnmCrdSdI3hHIau48R0lBMhWiGgb1oJwrRWykGoXg2DbKwUvWJYCMU4xwLYUfV-qbuduwl6C7tfGPU2usnErzoYp_--8e5ab8KtFpwz0fJS4M19gRi-zJCynlyyMI7GQ5iTphQTSQilbUFf_4PehDn6Mt5Cld3IQtGFsjGkFGF4eAzBeme-XszXxXy9N1_flaRXj8d4SPltdQHYAqRy5TcQ__T-T9lfi3y50A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2201701757</pqid></control><display><type>article</type><title>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Full-Text Journals in Chemistry (Open access)</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Schwich, Esther ; Rebmann, Vera ; Michita, Rafael Tomoya ; Rohn, Hana ; Voncken, Jan Willem ; Horn, Peter A. ; Kimmig, Rainer ; Kasimir-Bauer, Sabine ; Buderath, Paul</creator><creatorcontrib>Schwich, Esther ; Rebmann, Vera ; Michita, Rafael Tomoya ; Rohn, Hana ; Voncken, Jan Willem ; Horn, Peter A. ; Kimmig, Rainer ; Kasimir-Bauer, Sabine ; Buderath, Paul</creatorcontrib><description>Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the HLA-G 3′ untranslated region (UTR) regulate HLA-G expression, we investigated HLA-G 3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the HLA-G 3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the HLA-G 3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-41900-z</identifier><identifier>PMID: 30932005</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/51 ; 3' Untranslated regions ; 3' Untranslated Regions - genetics ; 38 ; 38/23 ; 38/77 ; 45 ; 631/250/248 ; 631/250/580 ; 692/4028/67/1517/1709 ; Adult ; Aged ; Aged, 80 and over ; Alleles ; Carcinoma, Ovarian Epithelial - genetics ; Carcinoma, Ovarian Epithelial - metabolism ; Carcinoma, Ovarian Epithelial - pathology ; Female ; Gene Frequency ; Genetic Predisposition to Disease - genetics ; Genotype ; Genotypes ; Haplotypes ; Histocompatibility antigen HLA ; HLA-G Antigens - genetics ; HLA-G Antigens - metabolism ; Homozygosity ; Humanities and Social Sciences ; Humans ; Kaplan-Meier Estimate ; Metastases ; Middle Aged ; multidisciplinary ; Neoplasm Staging ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Polymorphism, Single Nucleotide ; Science ; Science (multidisciplinary) ; Single-nucleotide polymorphism ; Tumor cells</subject><ispartof>Scientific reports, 2019-04, Vol.9 (1), p.5407, Article 5407</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</citedby><cites>FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2201701757/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2201701757?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30932005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwich, Esther</creatorcontrib><creatorcontrib>Rebmann, Vera</creatorcontrib><creatorcontrib>Michita, Rafael Tomoya</creatorcontrib><creatorcontrib>Rohn, Hana</creatorcontrib><creatorcontrib>Voncken, Jan Willem</creatorcontrib><creatorcontrib>Horn, Peter A.</creatorcontrib><creatorcontrib>Kimmig, Rainer</creatorcontrib><creatorcontrib>Kasimir-Bauer, Sabine</creatorcontrib><creatorcontrib>Buderath, Paul</creatorcontrib><title>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the HLA-G 3′ untranslated region (UTR) regulate HLA-G expression, we investigated HLA-G 3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the HLA-G 3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the HLA-G 3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.</description><subject>13</subject><subject>13/51</subject><subject>3' Untranslated regions</subject><subject>3' Untranslated Regions - genetics</subject><subject>38</subject><subject>38/23</subject><subject>38/77</subject><subject>45</subject><subject>631/250/248</subject><subject>631/250/580</subject><subject>692/4028/67/1517/1709</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alleles</subject><subject>Carcinoma, Ovarian Epithelial - genetics</subject><subject>Carcinoma, Ovarian Epithelial - metabolism</subject><subject>Carcinoma, Ovarian Epithelial - pathology</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Haplotypes</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-G Antigens - genetics</subject><subject>HLA-G Antigens - metabolism</subject><subject>Homozygosity</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Neoplasm Staging</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Single-nucleotide polymorphism</subject><subject>Tumor cells</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kc9qFTEUxgdRbKl9ARcScCPYsfk3yWQjlGJvhQtu6jpkMmduU2aSa5Ip2JWv4Wv4SD6JuXdqrS4MgXyH_M45Ofmq6iXB7whm7WnipFFtjYmqOVEY13dPqkOKeVNTRunTR_qgOk7pBpfVUFXY59UBw4rREh9W3y_XZ_UKsZ_ffqDZ52h8Gk2GHkXYuODRrYnO-JzQW0ZauTpdneyUEkUh4_sSYNZcoR4G5wH1zkyQo7NmRHZ0fi9SNnlOe7p3CUwCFOZswwTIeQRbl69hdAUMSzNkjbcQX1TPBjMmOL4_j6rPFx-uzi_r9afVx_OzdW255LnmCrdSdI3hHIau48R0lBMhWiGgb1oJwrRWykGoXg2DbKwUvWJYCMU4xwLYUfV-qbuduwl6C7tfGPU2usnErzoYp_--8e5ab8KtFpwz0fJS4M19gRi-zJCynlyyMI7GQ5iTphQTSQilbUFf_4PehDn6Mt5Cld3IQtGFsjGkFGF4eAzBeme-XszXxXy9N1_flaRXj8d4SPltdQHYAqRy5TcQ__T-T9lfi3y50A</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Schwich, Esther</creator><creator>Rebmann, Vera</creator><creator>Michita, Rafael Tomoya</creator><creator>Rohn, Hana</creator><creator>Voncken, Jan Willem</creator><creator>Horn, Peter A.</creator><creator>Kimmig, Rainer</creator><creator>Kasimir-Bauer, Sabine</creator><creator>Buderath, Paul</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190401</creationdate><title>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</title><author>Schwich, Esther ; Rebmann, Vera ; Michita, Rafael Tomoya ; Rohn, Hana ; Voncken, Jan Willem ; Horn, Peter A. ; Kimmig, Rainer ; Kasimir-Bauer, Sabine ; Buderath, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>13</topic><topic>13/51</topic><topic>3' Untranslated regions</topic><topic>3' Untranslated Regions - genetics</topic><topic>38</topic><topic>38/23</topic><topic>38/77</topic><topic>45</topic><topic>631/250/248</topic><topic>631/250/580</topic><topic>692/4028/67/1517/1709</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alleles</topic><topic>Carcinoma, Ovarian Epithelial - genetics</topic><topic>Carcinoma, Ovarian Epithelial - metabolism</topic><topic>Carcinoma, Ovarian Epithelial - pathology</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Haplotypes</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-G Antigens - genetics</topic><topic>HLA-G Antigens - metabolism</topic><topic>Homozygosity</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Neoplasm Staging</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Single-nucleotide polymorphism</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwich, Esther</creatorcontrib><creatorcontrib>Rebmann, Vera</creatorcontrib><creatorcontrib>Michita, Rafael Tomoya</creatorcontrib><creatorcontrib>Rohn, Hana</creatorcontrib><creatorcontrib>Voncken, Jan Willem</creatorcontrib><creatorcontrib>Horn, Peter A.</creatorcontrib><creatorcontrib>Kimmig, Rainer</creatorcontrib><creatorcontrib>Kasimir-Bauer, Sabine</creatorcontrib><creatorcontrib>Buderath, Paul</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwich, Esther</au><au>Rebmann, Vera</au><au>Michita, Rafael Tomoya</au><au>Rohn, Hana</au><au>Voncken, Jan Willem</au><au>Horn, Peter A.</au><au>Kimmig, Rainer</au><au>Kasimir-Bauer, Sabine</au><au>Buderath, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>5407</spage><pages>5407-</pages><artnum>5407</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the HLA-G 3′ untranslated region (UTR) regulate HLA-G expression, we investigated HLA-G 3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the HLA-G 3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the HLA-G 3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30932005</pmid><doi>10.1038/s41598-019-41900-z</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2019-04, Vol.9 (1), p.5407, Article 5407
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6443684
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Full-Text Journals in Chemistry (Open access); PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 13
13/51
3' Untranslated regions
3' Untranslated Regions - genetics
38
38/23
38/77
45
631/250/248
631/250/580
692/4028/67/1517/1709
Adult
Aged
Aged, 80 and over
Alleles
Carcinoma, Ovarian Epithelial - genetics
Carcinoma, Ovarian Epithelial - metabolism
Carcinoma, Ovarian Epithelial - pathology
Female
Gene Frequency
Genetic Predisposition to Disease - genetics
Genotype
Genotypes
Haplotypes
Histocompatibility antigen HLA
HLA-G Antigens - genetics
HLA-G Antigens - metabolism
Homozygosity
Humanities and Social Sciences
Humans
Kaplan-Meier Estimate
Metastases
Middle Aged
multidisciplinary
Neoplasm Staging
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Polymorphism, Single Nucleotide
Science
Science (multidisciplinary)
Single-nucleotide polymorphism
Tumor cells
title HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A19%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-G%203%E2%80%B2%20untranslated%20region%20variants%20+3187G/G,%20+3196G/G%20and%20+3035T%20define%20diametrical%20clinical%20status%20and%20disease%20outcome%20in%20epithelial%20ovarian%20cancer&rft.jtitle=Scientific%20reports&rft.au=Schwich,%20Esther&rft.date=2019-04-01&rft.volume=9&rft.issue=1&rft.spage=5407&rft.pages=5407-&rft.artnum=5407&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-41900-z&rft_dat=%3Cproquest_pubme%3E2201711228%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2201701757&rft_id=info:pmid/30932005&rfr_iscdi=true